Fidelity High Yield Factor ETF (ARCA: FDHY)

Latest news for Fidelity High Yield Factor ETF (ARCA:FDHY)

Fidelity High Yield Factor ETF

The fund normally invests at least 80 percent of its assets in debt securities rated below investment grade (also referred to as high yield debt securities or junk bonds). It uses the ICE BofA BB-B US High Yield Constrained Index as a guide in structuring the fund and selecting its investments as it relates to credit quality distribution and risk characteristics. The fund normally invests primarily in securities rated BB or B by S&P, Ba or B by Moodys, comparably rated by at least one nationally recognized credit rating agency, or, if unrated, considered by FMRC to be of comparable quality.

Long Ideas

Bonds

Specialty ETFs

New ETFs

Trading Ideas

ETFs

FCOR

FDHY

Fidelity Expands ETF Roster With 2 Bond Funds

By <a href="https://www.benzinga.com/author/todd-harrison" target="_blank" rel="noreferrer noopener">Todd Harrison</a> via <a href="https://substack.com/@toddharrison" target="_blank" rel="noreferrer noopener">Cannabis Confidential</a> (July 22)
With U.S. President Joe Biden stepping aside for the presidential race and endorsing Vice President Kamala Harris, her potential candidacy for the 2024 election against Donald Trump brings attention to her stance on multiple issues, including cannabis.
Although Harris was once a prosecutor, she publicly shifted her position several years ago and supported legalization, and she has since endeavored to champion cannabis. If she gets the Democratic nod, she's widely expected to maintain her policy stance.
<ul>
<li><a href="https://substack.com/@toddharrison" target="_blank" rel="noreferrer noopener">Click here</a> to get Cannabis Confidential delivered to your inbox daily.</li>
</ul>
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7383e053-253e-4ce4-8943-dd4781cf022a_1179x524.jpeg" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7383e053-253e-4ce4-8943-dd4781cf022a_1179x524.jpeg" alt="" /></a></figure>
PA System
Despite earlier reports that recreational cannabis legalization in Pennsylvania may have to wait until next year after being left out of the state budget, the spokeswoman of a pro-marijuana coalition said there's still a window this coming fall for a bill to get through to Gov. Josh Shapiro's desk.
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"The pieces are aligned and teed up right now in a way that makes a fall session passage of adult use very likely." Brit "da cramper" Crampsie of Responsible PA.
</blockquote>
Buck-eyed
Ohio's adult-use cannabis market is officially up and running—well sorta, with four cultivators and six processors now online.
Another 31 cultivators, 36 processors, seven testing laboratories and 133 dispensaries are in the provisional licensing queue for certificates, pending final requirements.
<a href="https://www.youtube.com/watch?v=5Ktk39ZtPMU">Tha Shiznit &#x1f3b6;</a>
A new poll found that more Americans smoke cannabis on a daily basis than drink alcohol every day—and alcohol drinkers are three times more likely to say they would benefit from limiting use than cannabis consumers are.
Stocks &amp; Stuff
The D.C. drama drew fresh attention to Cannaland as the presidential race just shifted the political calculous around issues that appeal to young and/ or minority voters.
U.S. canna ETF MSOS finished the session +5%, albeit still under technical resistance.
Below, we'll top-line today's reaction to yesterday's news, explore a few analyst takes on the implications, finger the level of lore for holders galore, update the size of the respective Florida war chests, and continue to sniff at potential CPG involvement.
All that and more, just scroll down.
<a target="_blank" rel="noreferrer noopener" href="https://substack.com/discover/stocks/SPY">SPY 0.95%↑</a> <a target="_blank" rel="noreferrer noopener" href="https://substack.com/discover/stocks/QQQ">QQQ 1.33%↑</a> <a target="_blank" rel="noreferrer noopener" href="https://substack.com/discover/stocks/IWM">IWM 1.56%↑</a> <a target="_blank" rel="noreferrer noopener" href="https://substack.com/discover/stocks/MSOS">MSOS 2.09%↑</a> ETF Notional: $88M
Top Stories
<ul>
<li><a href="https://www.forbes.com/sites/dariosabaghi/2024/07/22/where-does-kamala-harris-stand-on-marijuana/">Where Does Kamala Harris Stand On Marijuana?</a></li>
<li><a href="https://www.marijuanamoment.net/more-americans-smoke-marijuana-every-day-than-drink-alcohol-on-a-daily-basis-poll-shows/">More Americans Smoke Cannabis Every Day Than Drink Alcohol Daily</a></li>
<li><a href="https://www.cannabisbusinesstimes.com/news/ohio-recreational-marijuana-licenses-certificates-start-sales-market-cultivation-dispensary-when-where-buy/">Ohio Issues 1st Batch of Adult-Use Cannabis Certificates, Igniting the Market</a></li>
<li><a href="https://www.greenmarketreport.com/pennsylvania-cannabis-coalition-says-theres-still-a-path-for-adult-use-legalization/?utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=Newsletter-MorningRise-20240722">Pennsylvania cannabis coalition says there's still a path for adult-use legalization</a></li>
<li><a href="https://www.marijuanamoment.net/marijuana-rescheduling-would-create-over-50000-new-jobs-industry-group-tells-dea-on-last-day-of-public-comment-period/">Marijuana Rescheduling Would Create Over 50,000 New Jobs, Industry Group Tells DEA On Last Day Of Public Comment Period</a></li>
<li><a href="https://www.marijuanamoment.net/state-marijuana-regulators-push-feds-to-explain-how-rescheduling-will-impact-enforcement-banking-research-and-more/">State Marijuana Regulators Push Feds To Explain How Rescheduling Will Impact Enforcement, Banking, Research And More</a></li>
<li><a href="https://abc7ny.com/post/bronx-marijuana-bust-nypd-nyc-sheriffs-office-seize-millions-illegal-cannabis-products-mott-haven-nyc/15077346/">Officials seize $10 Million in illegal cannabis products in Bronx bust</a></li>
<li><a href="https://norml.org/blog/2024/07/18/american-nurses-association-provides-public-comments-to-dea-in-support-of-reclassifying-cannabis/">American Nurses Association Provides Public Comments to DEA in Support of Reclassifying Cannabis</a></li>
<li><a href="https://www.marijuanamoment.net/senators-push-va-to-create-medical-marijuana-standard-of-care-as-rescheduling-process-finishes/">Senators Push VA To Create Medical Marijuana ‘Standard Of Care' As Rescheduling Process Finishes</a></li>
<li><a href="https://www.reuters.com/legal/judge-wont-halt-new-york-city-crackdown-unlicensed-cannabis-sales-2024-07-18/">Judge won&#8217;t halt New York City crackdown on unlicensed cannabis sales</a></li>
</ul>
Industry Headlines
<ul>
<li><a href="https://finance.yahoo.com/news/glass-house-brands-announces-court-113000862.html?guccounter=1&amp;guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&amp;guce_referrer_sig=AQAAAAc3I94APN0mj3qcWqxBOtCUD5ctDjOBqmB_wB10kKNMsoFQtDwVxdDdz_VbbqQDnbJSJXAMwtm7D1uPz-eN3o1Q-nwzy1t3wqHKfJ2lNmSgMxN59c3auvR3a59UYfyPjftvIlwm8s89877TYTF3j3lr6FEw6ueXrhaqRUfycIPr">Glass House Brands Announces Court Dismissal of Catalyst Lawsuit</a></li>
<li><a href="https://www.globenewswire.com/en/news-release/2024/07/22/2916431/0/en/Tilray-Receives-First-New-Cannabis-Cultivation-License-in-Germany-Under-New-Regulations.html">Tilray Receives First New Canna Cultivation License in Germany Under New Regs</a></li>
<li><a href="https://www.cannabisbusinesstimes.com/news/marimed-hagerstown-maryland-cultivation-facility-expandsion-flower-concentrates-edibles/">MariMed Doubles Cannabis Cultivation Flower Capacity in Maryland Facility</a></li>
</ul>
Pregame (<a href="https://x.com/todd_harrison/status/1815357303421272563">written 8:00 AM</a>).
We fire up this five-session set on the heels of President Joe Biden stepping down and V.P. Kamala Harris the odds-on fave (84%) to assume the top of the ticket.
Investors are understandably <s>angry as f&#x2A;ck</s> wary but this shake-up should help canna remain front and center for the next three months. Ditto the VP pick (there are some genuine advocates (Shapiro, Beshear, et al) and, lest you forgot, today is the final day of the comment period, which ushers in the next phase of rescheduling (ALJ decision).
Technically, the song remains the same. MSOS has to reclaim $8—bc Eight is Enough, already—if it is to begin a second-half rally or, at the very least, continue it&#8217;s bipolar stroller of &#8220;so hot&#8221; (Q1) to &#8220;so not&#8221; (Q2), before the mood flips, again.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F26276f90-c9a1-4696-89f6-6902f5cf833f_736x530.gif" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F26276f90-c9a1-4696-89f6-6902f5cf833f_736x530.gif" alt="" /></a></figure>
MSOS coming into the week
Between the Bells (→ real-time market updates are now offered daily on <a href="https://x.com/todd_harrison">X-subs</a><a href="https://x.com/todd_harrison">).</a>
There was a fair amount of reflexive trepidation early as our &#8216;abbreviated&#8217; market digested the news. I preferred that to a low volume gap higher but either way and no matter what, the bulls need to earn the market&#8217;s respect and there's only one way to do that, via higher prices.
Earnings are approaching, which will likely continue the recent trend of meh reports with muted growth given a dearth of capex (in response to an onerous tax regime). We expect continued bifurcation (winners vs. sinners) but we also know that, with the comment period coming to an end today, <a href="https://toddharrison.substack.com/p/seismic-shifts?utm_source=publication-search">seismic shifts</a> are also in play.
Kamala has been extremely vocal on cannabis (both <a href="https://toddharrison.substack.com/p/in-too-veep?utm_source=publication-search">rescheduling in this term</a> and &#8216;<a href="https://toddharrison.substack.com/p/dc-dogs-and-ponies?utm_source=publication-search">finishing the job</a>&#8216; in 2.0) but of course, there&#8217;s the matter of 1. her securing the top of the ticket and 2. the election in 105 days, where <a href="https://www.predictit.org/markets/detail/7456/Who-will-win-the-2024-US-presidential-election">current odds</a> favor Trump 60-40.
From here to there, Kamala must show the world she has in fact changed her stripes from her days as a prosecutor—where she locked people up for cannabis—and the space should better reflect those potential implications if her numbers are able to lift.
And then there's the GOP candidate, and the potential for <a href="https://toddharrison.substack.com/p/unlikely-allies">Unlikely Allies</a>.
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7e6aa30c-e34b-495a-a918-4a86823d2ade_1281x2173.jpeg" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7e6aa30c-e34b-495a-a918-4a86823d2ade_1281x2173.jpeg" alt="" /></a></figure>
Around 2PM, we saw a Pelosi pop take MSOS to session highs ($7.82, +5.5%)…
<figure class="wp-block-image"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9b9c379b-760d-49fa-b02f-7a23bef56ff6_1479x1635.jpeg" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9b9c379b-760d-49fa-b02f-7a23bef56ff6_1479x1635.jpeg" alt="" /></a></figure>
…but with volumes so anemic, and all of $88M notional trading by the end of the day, the market, as a shadow of its former pre-custody f&#x2A;ckery self, continued to more or less trade by appointment and as a public reflection of private equity.
Random Thought
We focus on <a href="https://advisorshares.com/etfs/msos/">the ETF</a> a lot because it&#8217;s the dog with 25 tails and the driver of price in the absence of custody. Two names we own away from the MSO space are $VFF (<a href="https://toddharrison.substack.com/p/it-takes-a-village">big fan</a>) and <a target="_blank" rel="noreferrer noopener" href="https://substack.com/discover/stocks/MAPS">MAPS 8.33%↑</a>, as a listed and liquid trading vehicle.
AGP on U.S. cannabis
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">We view one of the most important takeaways from VP Harris being endorsed by President Biden as the new Democrat nominee as things staying status quo as it relates to cannabis reform, given VP Harris is part of the current administration.
As a reminder, the comment period for the proposed rule to reschedule cannabis to a Schedule III drug ends today, and we expect there to be building speculation as to when a final rule comes heading into the election.
While there could have been some risk to a shift in priorities with a different Democratic candidate, VP Harris increases the likelihood of priorities remaining – and we believe that includes a final rule on rescheduling.
This view is due to the fact of rescheduling allowing VP Harris to demonstrate 1), her ability to drive reform regarding an issue she has been supportive of (before Biden), 2) demonstrating the ability of the administration to deliver on a priority issue, and 3) that current efforts will continue with Biden "passing the baton" to VP Harris.
For these reasons, we view VP Harris as the Democratic nominee as favorable for the prospect of a final rule on rescheduling ahead of the election.
</blockquote>
Beacon on U.S. cannabis:
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">&#8220;We believe [JB&#8217;s] final months will be focused on policy wins designed to support other Democrats. Pushing Rescheduling across the finish line will now be part of Biden's legacy. Absent a hearing, we could see a final rule by September/October.&#8221;
</blockquote>
Beacon on Florida cannabis:
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">The political action committee supporting the Florida adult-use legalization measure on this November's ballot has now raised over $61M, following $314k in additional donations during the week ending July 12th.
The opposition PAC started by Governor DeSantis had received $129k in donations as of the same cutoff date, though the state's hemp producers have reportedly pledged $5M to the Republican Party to help defeat the measure.
</blockquote>
Jefferies on U.S. cannabis:
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow"><a href="https://www.businesswire.com/news/home/20231106603579/en/Organigram-Announces-C124.6-Million-Investment-from-BAT-and-Creation-of-%E2%80%9CJupiter%E2%80%9D-Strategic-Investment-Pool">The OGI + BAT relationship</a> shows that an appetite for U.S. exposure among broader CPG is building, potentially influenced by the reform momentum at the federal level, and specifically plans to reschedule cannabis this year. If that happens, along with other potential measures like SAFER and a Garland Memo, we think it is very possible we see other CPG looking to get exposure over the next 12 months.
</blockquote>
Stems &amp; Seeds
<a href="https://www.sciencedirect.com/science/article/abs/pii/S1568163724002046">A review concluded that CBD shows various clinical benefits against various neurological and neurodegenerative diseases.</a>
<a href="https://www.marijuanamoment.net/cannabis-is-more-effective-in-treating-musculoskeletal-pain-than-traditional-medications-are-patients-say-in-new-study/">Cannabis More Effective For Musculoskeletal Pain Than Traditional Medications</a>
Housekeeping
I&#8217;ll be heading to Nashville late Wednesday (through Friday) for <a href="https://karate.com/events/kc48">The Karate Combat Championships</a> sponsored by <a href="https://tempters.us/">Tempters</a>.
I've never been to an event like this—or Nashville, for that matter—so I look forward to supporting our port-co/ client and experiencing something new with an investor/ pal who I've known since high school in Woodland Hills, CA. It&#8217;s the little things.
ICYMI, all payments to Cannabis Confidential have been <a href="https://toddharrison.substack.com/p/america-the-beautiful">halted until further notice</a> but (as you can see) I'll continue to write gratis when there is something to say.
Have a safe night and please <a href="https://joelpollack.com/">enjoy responsibly</a>.
If you'd like to help Mission [Green] change federal cannabis policies, please <a href="https://www.projectmissiongreen.org/donate">click here.</a>
CB1 has positions in / advises some of the companies mentioned and nothing contained herein should be considered advice
This article is from an external unpaid contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.
Cover image made with AI

Cannabis

Politics

MAPS

MSOS

Did Pot Just Pivot? Cannabis Preps For Possible Presidential Run

SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) reported its second-quarter financial results Monday. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/07/n39892941/sap-announces-q2-2024-results">details from the report.&nbsp;</a>
The Details: SAP reported quarterly earnings of 82 cents per share which missed the analyst consensus estimate of $1.19 by 31.26%. Quarterly sales came in at $8.92 billion which missed the analyst consensus estimate of $8.96 billion by 0.42% and represents an 8.81% increase over sales from the same period last year.
Cloud revenue grew 25%, underpinned by 33% Cloud ERP Suite revenue growth, all at nominal and constant currencies, and the company reported its current cloud backlog increased by 28%, both at nominal and constant currencies. IFRS cloud gross profit grew 29% and non-IFRS cloud gross profit grew 28%. 
Read Also: <a href="https://www.benzinga.com/news/24/07/39891006/sunpower-stock-attempts-to-bounce-back-whats-going-on">SunPower Stock Attempts To Bounce Back: What&#8217;s Going On?</a>
&#8220;Our cloud growth momentum remained strong in Q2, with Business AI enabling many deals. We continue to execute on our transformation with great discipline, leading to an increase in our operating profit ambition for 2025. At the same time, we continue to invest into our transformation to be the leader in Business AI. Given our progress and strong pipeline, we are confident to achieve accelerating topline growth through 2027,&#8221; said Christian Klein, SAP&#8217;s CEO. 
Outlook:&nbsp;SAP reiterated its fiscal year 2024 outlook and sees cloud revenue in a range of $18.5 billion and $18.84 billion and non-IFRS operating profit between $8.28 billion and $8.6 billion. The company expects fiscal year 2025 cloud revenue of more than $23.41 billion and non-IFRS operating profit of approximately $11.11 billion. 
SAP Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, SAP shares are up 4.80% after-hours at $210.10 at the time of publication Monday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39891755/whats-going-on-with-coinbase-shares-today">What&#8217;s Going On With Coinbase Shares Today?</a></li>
</ul>
Image: Courtesy of SAP

Earnings

News

After-Hours Center

Movers

SAP Stock Is Up After Q2 Results: Here's A Look At The Details

<div>The declaration of a quarterly cash dividend of&nbsp;$0.16&nbsp;per share on its outstanding common stock. The dividend is payable on September 13, 2024 to shareholders of record at the close of business on August 29, 2024.</div>
<div>&nbsp;</div>
<div>The company expects&nbsp;repurchase to be executed at management&#39;s discretion through the end of the 4th&nbsp;quarter of 2025. This approval is in addition to the&nbsp;$50 million&nbsp;remaining under the stock repurchase program announced on July 24, 2023.</div>

Dividends

Buybacks

First BanCorp Plans New Repurchase Program Of Up To $250M That Could Include Repurchases Of Common Stock Or Junior Subordinated Debentures

Citigroup analyst Jason Bazinet maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Neutral and raises the price target from $660 to $675.

Price Target

Analyst Ratings

NFLX

Citigroup Maintains Neutral on Netflix, Raises Price Target to $675

SmartFinancial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMBK#NYSE">SMBK</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.39 by 17.95 percent. This is a 11.54 percent decrease over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $40.418 million which beat the analyst consensus estimate of $40.072 million by 0.86 percent. This is a 4.43 percent increase over sales of $38.705 million the same period last year.

Earnings Beats

SMBK

SmartFinancial Q2 2024 Adj EPS $0.46 Beats $0.39 Estimate, Sales $40.418M Beat $40.072M Estimate

Medpace Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares are falling in Monday&#8217;s after-hours session after the company reported mixed financial results and <a href="https://www.benzinga.com/pressreleases/24/07/b39893344/medpace-holdings-inc-reports-second-quarter-2024-results">adjusted its forward guidance</a>.
<ul>
<li>Q2 Revenue: $528.1 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $528.44 million</li>
</ul>
<ul>
<li>Q2 EPS: $2.75, versus estimates of $2.54</li>
</ul>
Total revenue was up 14.6% on a year-over-year basis. Medpace said its backlog increased 13.7% year-over-year to $2.925 billion. 
The company generated $116.4 million in cash flow during the quarter. Medpace ended the quarter with $510.9 million in cash and cash equivalents. 
Outlook: Medpace revised its full-year 2024 revenue forecast from a range of $2.15 billion to $2.2 billion to a new range of $2.125 billion to $2.175 billion versus estimates of $2.17 billion. 
In contrast, Medpace raised its full-year 2024 earnings outlook from a range of $10.79 to $11.47 per share to a new range of $11.24 to $11.93 per share versus estimates of $11.25 per share. 
Management will hold a conference call to discuss these results Tuesday morning at 9 a.m. ET.
See Also: <a href="https://www.benzinga.com/news/earnings/24/07/39894221/cadence-design-reports-q2-results-forward-guidance-heres-the-details">Cadence Design Reports Q2 Results, Forward Guidance: Here&#8217;s The Details</a>
MEDP Price Action: <a href="https://www.benzinga.com/quote/MEDP">Medpace shares</a> were down 13.08% at $380 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: 3844328 from Pixabay.

Guidance

Health Care

MEDP

Medpace Holdings Stock Tumbles On Q2 Earnings: What Investors Need To Know

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is under scrutiny again due to the intensity of a battery fire and the potential <a href="https://www.benzinga.com/topic/pollution">spread of hazardous materials</a>.
What Happened: A Tesla vehicle burst into flames at a &#8220;Supercharger&#8221; station in Pennsylvania earlier this month.
The car proceeded to melt, resulting in a <a href="https://www.benzinga.com/top-stories/24/06/39274483/elon-musk-alright-sure-to-potential-avoid-highways-navigation-feature">temporary road closure</a>, according to a <a href="https://www.pcmag.com/news/tesla-catches-fire-burns-to-a-crisp-at-supercharging-station">report</a> from PCMag. 
When firefighters arrived, they targeted the fire using a nearby hydrant. After most of the fire was extinguished, first responders began the cooling process of the vehicle&#8217;s battery.
&#8220;These are not easy fires to put out, and the hazmat concerns they pose are difficult to mitigate,&#8221; the Upper Allen Fire Department reportedly said. 
Check This Out: <a href="https://www.benzinga.com/exclusives/24/07/39886192/exclusive-tesla-an-elon-musk-and-a-technology-story-first-ev-story-last-market-strategist-explains-w">EXCLUSIVE: Tesla &#8216;An Elon Musk And A Technology Story First, EV Story Last&#8217; — Market Strategist Explains Why To Buy The Stock</a>
Why It Matters: This isn&#8217;t the first time a Tesla-related fire has been reported. In June, a Tesla charger seemingly malfunctioned and set the home of <a href="https://www.benzinga.com/general/sports/24/06/39536942/tesla-charger-blamed-for-house-fire-by-nfl-players-wife-lucky-to-be-alive">NFL star Randall Cobb ablaze</a>.
In September, a Tesla owner told Business Insider that his Model Y suddenly began shaking and, after pulling over, <a href="https://www.benzinga.com/news/23/05/32539341/model-y-burst-into-flames-on-side-of-the-road-tesla-told-owner-to-bring-fully-burned-vehicle-to-serv">burst into flames</a>.
A similar scenario <a href="https://www.benzinga.com/general/22/05/27348704/watch-tesla-engulfed-in-flames-driver-escapes-through-window-in-time">occurred in 2022</a>. See below. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Passed a stalled <a href="https://twitter.com/Tesla?ref_src=twsrc%5Etfw">@Tesla</a> on the way to work. Well that escalated quickly! <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a> how does this happen?<a href="https://twitter.com/hashtag/fire?src=hash&amp;ref_src=twsrc%5Etfw">#fire</a> <a href="https://twitter.com/hashtag/error?src=hash&amp;ref_src=twsrc%5Etfw">#error</a> <a href="https://twitter.com/hashtag/electricvehicles?src=hash&amp;ref_src=twsrc%5Etfw">#electricvehicles</a> <a href="https://twitter.com/hashtag/Elon?src=hash&amp;ref_src=twsrc%5Etfw">#Elon</a> <a href="https://twitter.com/hashtag/batteries?src=hash&amp;ref_src=twsrc%5Etfw">#batteries</a> <a href="https://t.co/IK8inNB1Ft">pic.twitter.com/IK8inNB1Ft</a>
&mdash; SOV Distillery (@SonsofVancouver) <a href="https://twitter.com/SonsofVancouver/status/1527934071082393601?ref_src=twsrc%5Etfw">May 21, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
At the time, Tesla found itself under the scanner of the U.S. federal transport regulator — the National Highway Traffic Safety Administration — due to&nbsp;<a href="https://www.benzinga.com/government/22/05/27435318/brand-new-tesla-model-y-that-caught-fire-in-canada-reportedly-receives-nhsta-scrutiny">quality issues with its cars</a>.
In the case of <a href="https://www.benzinga.com/electric-vehicles">EVs</a>, the battery chemistry can cause the vehicle to enter into a phenomenon known as thermal runaway. This is when the battery cells begin self-heating and consume more oxygen, which can cause the flames to reignite repeatedly. 
Battery fires can also reportedly burn up to 1,000 degrees hotter than gas or diesel engine fires.
This latest Tesla fire, however, is particularly concerning given that it took place while the vehicle was charging. 
The exact cause of the fire has not been made public. Images from the scene appear to show that multiple Superchargers were damaged by the flames. 
Contrary to popular belief, EVs are <a href="https://www.topgear.com/car-news/mythbusting-evs/mythbusting-world-evs-are-electric-cars-susceptible-catching-fire">less prone</a> to fires compared to conventional internal combustion engine (ICE) vehicles. 
According to the National Fire Protection Agency, there are about 25 fires per year for every 100,000 electric vehicles. In contrast, there are more than 1,500 fires per year for every 100,000 ICE vehicles. It&#8217;s important to note that this data may be skewed since the average age of EVs is significantly lower than that of ICE vehicles.
TSLA Price Action: Tesla shares were up 5.35% at $252.03 at the time of publication Monday afternoon, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39884657/ford-gm-face-profit-decline-as-ev-sales-slow-and-cyber-outages-persist">Ford, GM Face Profit Decline As EV Sales Slow And Cyber Outages Persist</a></li>
<li><a href="https://www.benzinga.com/general/sports/24/06/39536942/tesla-charger-blamed-for-house-fire-by-nfl-players-wife-lucky-to-be-alive"></a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

General

TSLA

Tesla Vehicle Goes Up In Flames At Charging Station: 'These Are Not Easy Fires To Put Out,' First Responder Says

Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.94 by 2.13 percent. The company reported quarterly sales of $178.531 million which missed the analyst consensus estimate of $179.184 million by 0.36 percent. This is a 12.76 percent decrease over sales of $204.643 million the same period last year.

Earnings Misses

CATY

Cathay General Q2 2024 Adj EPS $0.96 Beats $0.94 Estimate, Sales $178.531M Miss $179.184M Estimate

This acquisition expands CRH&#39;s Americas Materials Solutions business in the state of Colorado, enhancing its ability to provide integrated solutions to customers in Colorado and surrounding states.

CRH Reports Acquisition Of Colorado-Based Building Materials Solutions Provider Ary Corporation; No Terms Disclosed

Israel has ordered residents in part of Khan Younis, a city in southern Gaza, to evacuate on Monday as it plans to take military action against Hamas.
What Happened: The evacuation order extended into parts of an area that Israel had previously designated a humanitarian zone.
Israel&#8217;s military is now pushing back the zone&#8217;s boundaries because Hamas had used the zone to launch rockets toward Israel, the New York Times <a href="https://www.nytimes.com/live/2024/07/22/world/israel-gaza-war-hamas?partner=slack&amp;smid=sl-share">reported</a>.
Residents were told to move temporarily closer to the coast to the "adjusted Humanitarian Area in Al-Mawasi."
Israeli fighter jets also struck Houthi military installations near Yemen&#8217;s Hodeidah Port on Saturday in response to a Houthi attack on Tel Aviv on Friday, CNN <a href="https://www.cnn.com/2024/07/21/middleeast/israel-strikes-houthi-rebels-explainer-intl/index.html">reported</a>. This marked the first time that Israel has attacked inside Yemen.
Since Hamas began attacking <a href="https://www.benzinga.com/news/23/10/35136071/israel-under-siege-unprecedented-hamas-attack-sparks-intense-clashes-netanyahu-says-we-are-at-war">Israel in early October</a>, the Houthis have been striking merchant vessels in the Red Sea in support of Gaza.
Also Read: <a href="https://www.benzinga.com/markets/asia/24/07/39851210/israeli-forces-intensify-attacks-in-gaza-southern-lebanon-ahead-of-netanyahus-visit-to-us-congress">Israeli Forces Intensify Attacks In Gaza, Southern Lebanon Ahead Of Netanyahu&#8217;s Visit To US Congress</a>
The Houthis said they fired more missiles toward Israel after an attack occurred near Hodeidah Port. Houthis promised a response that would be &#8220;huge and great&#8221; against Israel.
Israel&#8217;s Prime Minister Benjamin Netanyahu said Israel attacked the port because Iran used it to bring arms into Yemen.
"The port we attacked&nbsp;is&nbsp;not&nbsp;an innocent port. It was used for military purposes, it was used as an entry point for deadly weapons supplied to the Houthis&nbsp;by Iran," Netanyahu said in a statement on Saturday.
Houthi spokesperson Mohammed Abdulsalam criticized the attack as "brutal Israeli aggression" against Yemen.
Netanyahu also said the operation, which hit targets 1,118 miles from&nbsp;Israel's borders, showed&nbsp;Israel&nbsp;was&nbsp;serious about responding to threats.
"It makes it clear to our enemies that there is no place that the long arm of the State of Israel will not reach," Netanyahu said.
Why It Matters: The development comes just as Netanyahu prepares for tense meetings in Washington, D.C. to urge the Biden administration and Congress to support Israel&#8217;s war effort.
In March, Israel <a href="https://www.benzinga.com/news/24/03/37951362/israel-pulls-out-of-gaza-truce-negotiations-points-finger-at-hamas-for-escalating-conflict">withdrew</a> from truce discussions. 
Between Oct. 7, 2023, and July 22, 2024, at least 39,006 Palestinians were killed and 89,818 were injured in the war between Israel and Hamas, according to the Ministry of Health in Gaza.
Price Action: Exchange-traded funds with Israel exposure made gains into Monday&#8217;s late-afternoon trading.
<ul>
<li>&nbsp;iShares MSCI Israel ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EIS#NASDAQ">EIS</a>) gained 7.68%.</li>
<li>&nbsp;ARK Israel Innovative Technology ETF (IZRL) edged up 0.86%.</li>
<li>VanEck Israel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ISRA#NYSE">ISRA</a>) picked up 1.66%.</li>
<li>Amplify BlueStar Israel Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITEQ#NYSE">ITEQ</a>) rose 2.15%.</li>
<li>Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) went up 0.63%.</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/news/24/05/38909656/israel-intensifies-gaza-strikes-killing-at-least-28-palestinians-as-us-envoy-meets-with-netanyahu-to">Israel Intensifies Gaza Strikes, Killing At Least 28 Palestinians, As US Envoy Meets With Netanyahu To Prevent Full-Scale Assault</a></li>
</ul>
Image: Shutterstock

Government

Global

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

ITEQ

IZRL

Israel Orders Residents In Southern Gaza To Evacuate On Heels Of Houthi Drone Attack On Tel Aviv

Analysts' ratings for Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) over the last quarter vary from bullish to bearish, as provided by 18 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Reddit, revealing an average target of $64.61, a high estimate of $84.00, and a low estimate of $45.00. This current average has increased by 14.7% from the previous average price target of $56.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1721682074_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Reddit is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Shmulik</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Underperform</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$84.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$67.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Alan Gould</td>
<td>Loop Capital</td>
<td>Maintains</td>
<td>Hold</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Alan Gould</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Ben Black</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$63.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$61.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Mark Shmulik</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Underperform</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$59.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Reddit. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Reddit compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Reddit's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Reddit's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RDDT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Reddit analyst ratings.</a>
<h2>All You Need to Know About Reddit</h2>
Reddit Inc is engaged in providing internet content. The company provides online services that include gaming, sports, business, crypto, television and others.
<h3>Understanding the Numbers: Reddit's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Reddit showcased positive performance, achieving a revenue growth rate of 48.38% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: Reddit's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -236.69% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Reddit's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -80.69%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Reddit's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -31.84%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Reddit's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RDDT

Unveiling 18 Analyst Insights On Reddit

In the latest quarter, 6 analysts provided ratings for Lithia Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $286.33, a high estimate of $330.00, and a low estimate of $248.00. This current average has decreased by 6.38% from the previous average price target of $305.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1721682062_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Lithia Motors among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$330.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$270.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Ryan Sigdahl</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$310.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$248.00</td>
<td>$290.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lithia Motors. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lithia Motors compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Lithia Motors's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LAD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lithia Motors analyst ratings.</a>
<h2>All You Need to Know About Lithia Motors</h2>
Lithia Motors is a retailer of new and used vehicles and related services. The company offers about 50 brands of vehicles at nearly 500 stores globally across the US, Canada, and UK. The company has expanded largely through the acquisition of dealerships in smaller regional markets but now seeks to grow in any part of the US and we expect more deals over time in the US and, at times, abroad. Annual revenue in 2023 was $31 billion and we see over $50 billion possible in a few years. The US was 90% of 2023 revenue and the UK second at 6%, the latter should rise significantly with the Pendragon acquisition. In 2023, new-car sales were about 49% of total revenue. Lithia was founded in 1946, went public in 1996, and is the largest US auto dealer. It is based in Medford, Oregon.
<h3>Lithia Motors: Financial Performance Dissected</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Lithia Motors's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 22.77%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 1.9%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.59%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Lithia Motors's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.78% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Lithia Motors's debt-to-equity ratio is below the industry average at 2.08, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Lithia Motors Stock: Analyst Perspectives (6 Ratings)

In the last three months, 6 analysts have published ratings on Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Calix, revealing an average target of $40.83, a high estimate of $45.00, and a low estimate of $30.00. A decline of 8.92% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1721682054_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Calix by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>George Notter</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$30.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Christian Schwab</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Scott Searle</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$43.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Calix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Calix compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Calix's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Calix's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CALX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Calix analyst ratings.</a>
<h2>Delving into Calix's Background</h2>
Calix Inc develops, market and sell Calix cloud, systems and software platforms to enable service providers of all types and sizes to innovate and transform. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East &amp; Africa, Europe, Asia Pacific and other markets.
<h3>Calix: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Calix's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -9.48%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Calix's net margin excels beyond industry benchmarks, reaching 0.05%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.01%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Calix's ROA excels beyond industry benchmarks, reaching 0.01%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.02, Calix adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CALX

The Analyst Landscape: 6 Takes On Calix

Ratings for Valneva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Valneva and provided 12-month price targets. The average target is $26.0, accompanied by a high estimate of $26.00 and a low estimate of $26.00. Staying constant with the previous average price target, the current average remains unchanged. 
<img src="https://www.benzinga.com/files/images/story/2024/1721682031_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Valneva by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Valneva. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Valneva compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Valneva's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Valneva's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VALN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Valneva analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Valneva's Background</h2>
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, &amp; distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; &amp; Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.
<h3>Valneva's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Valneva faced challenges, resulting in a decline of approximately -2.25% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Valneva's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 179.86% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 37.11%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Valneva's ROA excels beyond industry benchmarks, reaching 12.24%. This signifies efficient management of assets and strong financial health.
Debt Management: Valneva's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.12, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VALN

What Analysts Are Saying About Valneva Stock

Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $80.57, a high estimate of $87.00, and a low estimate of $76.00. Marking an increase of 10.07%, the current average surpasses the previous average price target of $73.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1721682022_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Skechers USA. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$79.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$83.00</td>
<td>-</td>
</tr>
<tr>
<td>Christopher Nardone</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$87.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$81.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$76.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$76.00</td>
<td>$68.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Skechers USA. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Skechers USA compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Skechers USA's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Skechers USA's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SKX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Skechers USA analyst ratings.</a>
<h2>About Skechers USA</h2>
Skechers USA Inc is a lifestyle footwear company under the Skechers GO brand name. Products offered include various styles of women's shoes, men's shoes, girl's shoes, boy's shoes, performance shoes, and work shoes. Allied products offered are apparel, bags, eyewear, toys, and more. Its products are available for sale at department and specialty stores, athletic and independent retailers, boutiques, and internet retailers. The company's operating segments includes Wholesale and Direct-to-Consumer. It generates maximum revenue from the Wholesale segment.
<h3>Skechers USA: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Skechers USA's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 12.47%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Skechers USA's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Skechers USA's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.06% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.73%, the company showcases effective utilization of assets.
Debt Management: Skechers USA's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.42.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Skechers USA: 7 Analysts Share Their Views

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) has outperformed the market over the past 10 years by 6.55% on an annualized basis producing an average annual return of 17.46%. Currently, HCA Healthcare has a market capitalization of $85.22 billion. 
Buying $1000 In HCA: If an investor had bought $1000 of HCA stock 10 years ago, it would be worth $5,112.02 today based on a price of $325.38 for HCA at the time of writing.
<h3>HCA Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721682019_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In HCA Healthcare 10 Years Ago Would Be Worth Today

Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) has outperformed the market over the past 10 years by 4.37% on an annualized basis producing an average annual return of 15.28%. Currently, Abercrombie &amp; Fitch has a market capitalization of $8.08 billion. 
Buying $100 In ANF: If an investor had bought $100 of ANF stock 10 years ago, it would be worth $411.80 today based on a price of $158.01 for ANF at the time of writing.
<h3>Abercrombie &amp; Fitch's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721682014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today

15 analysts have expressed a variety of opinions on Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $82.73, along with a high estimate of $93.00 and a low estimate of $75.00. This current average has increased by 6.25% from the previous average price target of $77.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1721682010_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Fidelity National Info. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$79.00</td>
<td>-</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$93.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Moshe Katri</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$86.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>David Togut</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>David Togut</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$75.00</td>
<td>$62.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Fidelity National Info. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Fidelity National Info compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Fidelity National Info's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FIS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Fidelity National Info analyst ratings.</a>
<h2>All You Need to Know About Fidelity National Info</h2>
Fidelity National Information Services provides core processing and ancillary services to banks, but its business has expanded over time. By acquiring SunGard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS was providing payment processing services for merchants and holding leading positions in the United States and United Kingdom. But the company sold off a majority interest in Worldpay and now has only a minority stake.
<h3>Fidelity National Info: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Fidelity National Info's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 2.92%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Fidelity National Info's net margin is impressive, surpassing industry averages. With a net margin of 29.35%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Fidelity National Info's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.9%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Fidelity National Info's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.59% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.63.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 15 Analyst Ratings Have To Say About Fidelity National Info

Silicon Valley continues pushing the boundaries of mental health treatment, with Google (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) co-founder Sergey Brin now financing the development of a hallucinogen <a href="https://www.benzinga.com/markets/cannabis/22/04/25315203/what-is-iboga-and-how-does-it-compare-to-cannabis-exactly">derived from a West African shrub.</a>
<h3 class="wp-block-heading">Brin's Non-Profit Investment In Psychedelics</h3>
Brin is leveraging part of the profits from his 2021 Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stake sale to fund Catalyst4, a non-profit investment vehicle dedicated to innovative treatments and technologies. Catalyst4 has pledged approximately $15 million of a $25 million funding round for the psychedelic start-up Soneira, <a href="https://www.ft.com/content/5ed7daee-3d03-45d1-876b-52d81f0e2b68">reported</a> Financial Times citing sources familiar with the issue. Soneira is launching clinical trials to explore <a href="https://www.benzinga.com/topic/ibogaine">ibogaine</a>, a substance present in an African shrub, as a potential treatment for traumatic brain injury (TBI).
<h3 class="wp-block-heading">Ibogaine's Historical And Modern Significance</h3>
Ibogaine, traditionally used in spiritual rituals by tribes in Gabon, recently garnered interest from western mental health researchers and psychedelic advocates for its mind-altering effects. Earlier this year, a <a href="https://med.stanford.edu/news/all-news/2024/01/ibogaine-ptsd.html">Stanford University study</a> funded by Brin's charitable foundation reported that ibogaine therapy <a href="https://www.benzinga.com/general/biotech/24/01/36504333/breaking-ibogaine-therapy-show-promising-outcomes-for-veterans-with-trauma-brain-injury">improved mental health and cognitive function</a> in 30 U.S. military veterans with TBI. Stanford psychiatrist Nolan Williams, involved in the study, is now advising Soneira.
<h3 class="wp-block-heading">Mitigating Risks And Developing Synthetic Versions</h3>
Soneira is focusing on combining ibogaine with heart medications to reduce the risk of fatal cardiac arrhythmia, a known side effect of the plant. The biotech company is also developing a synthetic version of the compound, aiming to launch early-stage clinical trials with the new funding.
<h3 class="wp-block-heading">Silicon Valley&#8217;s Psychedelic Investment Surge</h3>
Brin's Catalyst4 represents the latest example of <a href="https://www.benzinga.com/markets/cannabis/24/04/38362918/psychedelic-productivity-peer-pressure-or-good-career-advice">Silicon Valley's growing interest in psychedelics</a>, both for personal use and as lucrative investments. Catalyst4 was funded by the $366 million from Brin's sale of his entire Tesla stake. Notably, Tesla founder Elon Musk has <a href="https://www.benzinga.com/markets/cannabis/22/10/29228362/elon-musks-exploratory-journeys-and-charts-explaining-benefits-of-psychedelics-over-alcohol">openly discussed using ketamine for depression</a>, while tech investor Peter Thiel was an early supporter of Atai Life Sciences, which is also <a href="https://www.benzinga.com/markets/cannabis/23/08/33721310/atais-q2-2023-plus-clinical-data-on-ibogaine-opioid-study-pipelines-psilocybin-dmt-ketamine-mdma">researching ibogaine</a> for opioid-use disorder treatment. Venture capitalists have invested nearly $180 million in psychedelic biotechs this year alone, with a record $528 million raised in 2021.
<h3 class="wp-block-heading">Brin's Commitment to Neurological Research</h3>
Through the Sergey Brin Family Foundation, Brin has invested hundreds of millions into research on neurodegenerative and psychological conditions. The Google co-founder, who discovered a genetic mutation heightening his risk of Parkinson's disease, uses Catalyst4 to fund breakthrough treatments for neurological disorders and climate change technologies. Catalyst4 had total assets of $430 million at the end of 2022.
<h3 class="wp-block-heading">Expanding Investment Interest</h3>
Around half a dozen parties have shown interest in investing in Soneira, including Helena Special Investments and LifeForce Capital. Helena Special Investments is behind Lykos Therapeutics, which awaits regulatory approval for MDMA as a treatment for PTSD. Soneira's funding round is expected to close after the summer.
Cover image made with AI

Psychedelics

GOOG

Google Co-Founder Sergey Brin Pledges $15M To Psychedelics Research Start-Up

Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) shares are climbing after the company reported its second-quarter financial results Monday. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/24/07/n39893908/nucor-reports-results-for-the-second-quarter-of-2024">figures from the report. </a>
The Details: Nucor reported quarterly earnings of $2.68 per share which beat the analyst consensus estimate of $2.35 by 14.04%. Quarterly sales came in at $8.08 billion, which beat the analyst consensus estimate of $7.69 billion by 5.13%.
A total of approximately 6.289 million tons were shipped to outside customers in the second quarter of 2024, a 1% increase compared with the first quarter of 2024 and a 5% decrease compared with the second quarter of 2023. 
Total steel mill shipments in the second quarter of 2024 were comparable to the first quarter of 2024 and decreased 2% as compared to the second quarter of 2023. Downstream steel product shipments to outside customers in the second quarter of 2024 increased 11% compared with the first quarter of 2024. 
Read Also: <a href="https://www.benzinga.com/news/24/07/39891006/sunpower-stock-attempts-to-bounce-back-whats-going-on">SunPower Stock Attempts To Bounce Back: What&#8217;s Going On?</a>
&#8220;While market conditions have softened compared to recent record-setting years, Nucor remains focused on its long-term growth strategy and has returned more than $1.7 billion to investors through June,&#8221; said Leon Topalian, Nucor&#8217;s CEO. 
&#8220;Nucor&#8217;s strategy to grow our core steelmaking operations and expand into steel-adjacent downstream markets positions the company to create attractive shareholder value and improve the company&#8217;s through-cycle earnings profile. I am incredibly proud of the 32,000 men and women of Nucor who are executing this growth plan while achieving the safest start to any year in Nucor&#8217;s history.&#8221;
Nucor will host a conference call Tuesday at 10 a.m. ET to discuss the results.
Outlook: Nucor said it expects earnings in the third quarter of 2024 to decrease compared to the second quarter of 2024. The largest driver for the expected decrease in earnings in the third quarter of 2024 is the expected decrease in earnings of the steel mills segment, primarily due to lower average selling prices.
NUE Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Nucor shares are up 1.02% after-hours at $165.01 at the time of publication Monday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39891755/whats-going-on-with-coinbase-shares-today">What&#8217;s Going On With Coinbase Shares Today?</a></li>
</ul>
Image: Courtesy of Nucor Corporation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Fidelity High Yield Factor ETF

News

Latest news for Fidelity High Yield Factor ETF (ARCA:FDHY)

Friday, June 15, 2018